|
DUS4L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.21199716929254E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.44169137633799E-15 |
| Normal-vs-Stage2 |
8.015600E-02 |
| Normal-vs-Stage3 |
2.0064999994851E-08 |
| Normal-vs-Stage4 |
1.45750078672791E-11 |
| Stage1-vs-Stage2 |
1.193740E-02 |
| Stage1-vs-Stage3 |
7.895000E-01 |
| Stage1-vs-Stage4 |
2.473600E-01 |
| Stage2-vs-Stage3 |
2.623700E-02 |
| Stage2-vs-Stage4 |
3.342300E-03 |
| Stage3-vs-Stage4 |
2.274800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.04818409297059E-13 |
| Normal-vs-AfricanAmerican |
2.32889999999264E-05 |
| Normal-vs-Asian |
6.10719996796405E-09 |
| Caucasian-vs-AfricanAmerican |
8.500800E-01 |
| Caucasian-vs-Asian |
8.303800E-01 |
| AfricanAmerican-vs-Asian |
9.532400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.96650037867607E-10 |
| Normal-vs-Female |
7.70450370168874E-11 |
| Male-vs-Female |
8.806800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62503344114384E-12 |
| Normal-vs-Age(41-60Yrs) |
9.45340028479791E-10 |
| Normal-vs-Age(61-80Yrs) |
4.32049999999906E-05 |
| Normal-vs-Age(81-100Yrs) |
4.736700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.573900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.493630E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.825600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.947950E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.389400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.927200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.877900E-02 |
| Classical-VS-Follicular |
4.27940000000682E-05 |
| Classical-VS-Other |
6.673600E-01 |
| Classical-VS-Normal |
1.62547753035369E-12 |
| Tall-VS-Follicular |
4.59480000003509E-06 |
| Tall-VS-Other |
7.665200E-01 |
| Tall-VS-Normal |
5.27510257697372E-11 |
| Follicular-VS-Other |
1.796300E-02 |
| Follicular-VS-Normal |
3.360100E-02 |
| Other-VS-Normal |
1.162300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.54259999510742E-08 |
| Normal-vs-N1 |
1.90669702249124E-12 |
| N0-vs-N1 |
3.339500E-03 |
|
|
